Latest posts from
What is New in Respiratory Medicine
Facebook Group
-
Thursday 29 Oct 2020
CPAP adherence not related to improvement in mortality or PFS in patients with OSA & ILD, except those requiring supplemental oxygen: https://hubs.ly/H0yXfbY0
-
Thursday 29 Oct 2020
Glad to present our latest study. Exposure to OCS or ICS is an independent risk factors for bone health in patients with asthma. Administration at the lowest possible level to maintain asthma control is recommended.
Background Inhaled (ICS) and oral (OCS) corticosteroids are used widely in asthma; however, the risk of osteoporosis and fragility fracture (FF) due to corticosteroids in asthma is not well-established. Methods We conducted two nested case-control studies using linked data from the Clinical Practice...
-
-
Thursday 29 Oct 2020
Impact of Corticosteroids in COVID-19 Outcomes: Systematic Review and Meta-Analysis
These results show evidence of mortality benefit in severely-ill COVID-19 treated with CS. CS are widely used in COVID-19 cases worldwide and a rapidly developing global pandemic warrants further high-quality clinical trials to define the most beneficial timing and dosing for CS.
A total of 73 studies with 21,350 COVID-19 cases were identified. CS use was widely reported in mechanically ventilated (35.3%), ICU (51.3%) and severe COVID-19 cases (40%). CS showed mortality benefit in severelly ill COVID-19 cases (OR 0.65, 95%CI 0.51-0.83, P=0.0006), however, no beneficial or harmful effects were noted amongst high- or low-dose CS regimens. Emerging evidence shows that low-dose CS do not have a significant impact in the duration of SARS-CoV-2 viral shedding. The analysis was limited by highly heterogeneous literature for high- and low-dose CS regimens.
Our results show evidence of mortality benefit in severely-ill COVID-19 treated with CS. CS are widely used in COVID-19 cases worldwide and a rapidly developing global pandemic warrants further high-quality clinical trials to define the most beneficial timing and dosing for CS.
-
Thursday 29 Oct 2020
Covid 19 continues to shake people globally. To keep ourselves updated and continue fighting this horrific disease we need to gear up with the the necessary information and education to handle patients. Also if you guys need CEUs it is an opportunity not to b missed.
ALL NEW TOPICS FOR COVID19 PANDEMIC 3:00 PM COVID Pandemic: The Evolution and Epidemiology Kenneth Miller MEd, MSRT, RRT-ACCS, RRT-NPS, AE-C, FAARC 4:00 PM Pathophysiology – How COVID Can Create Havoc in Your Body Kenneth Miller MEd, MSRT, RRT-ACCS, RRT-NPS, AE-C, FAARC 5:00 PM Management of Respiratory Failure In COVID Patients Albert Heuer PhD, MBA, RRT, RPFT. FAARC 6:00 PM An Clinician View From Inside The COVID ICU Albert Heuer PhD, MBA, RRT, RPFT. FAARC 7:00 PM COVID Pandemic: Treatments, Vaccinations, and Herd Immunity Terrence Shenfield MS, RRT-ACCS, RPFT, NPS, AE-C Click on the link below to sign up:
A & T Lecture COVID19 Pandemic. This webinar will be offered by experts Respiratory Conference that is considered live or traditional CEU’s.
-
Wednesday 28 Oct 2020
Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe AcuteRespiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis.
The use of ACE inhibitors might not increase the susceptibility of SARS-CoV-2 infection, severity of disease, and mortality in case-population and cohort studies. Additionally the use of ARBs, as opposed to ACE inhibitors, specifically augmented the risk of SARS-CoV-2 infection in younger subjects, without obvious effects on COVID-19 outcomes.
The viral spike coat protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) engages the human ACE (angiotensin-converting enzyme) 2 cell surface receptor to infect the host cells. Th
-
Wednesday 28 Oct 2020
Dual Bronchodilator in the Era of Triple Therapy
-
Wednesday 28 Oct 2020
Estamos viendo una afluencia increíble de pacientes a la UCI que nunca antes habíamos experimentado, por lo que el aumento de las complicaciones tromboembólicas es más obvio. En años anteriores, probablemente no hemos tenido suficientes pacientes en estado crítico en ningún momento para levantar la bandera sobre la tromboprofilaxis ”, comentó.
El estudio también encontró una alta tasa de complicaciones cardiovasculares. Están viendo un aumento en el riesgo de infarto de miocardio , que es de esperar en pacientes tan enfermos, pero también ven bastante fibrilación auricular nueva , miocarditis e insuficiencia cardíaca en pacientes que no siempre tienen una enfermedad cardiovascular subyacente. , él dijo.
However, new US data show the rates of thromboembolism are not as high as reported in earlier studies from Asia and appear similar to what would be expected in other very sick patients in ICU.
-
Wednesday 28 Oct 2020
Investigadores de la Universidad de Yale y el Instituto Broad del MIT y Harvard examinaron cientos de millones de células expuestas a los virus COVID-19 y MERS e identificaron docenas de genes que permiten que los virus se repliquen en las células y también aquellos que parecen cerrar la puerta. sobre el virus.
El papel pro-viral y anti-viral de estos genes ayudará a guiar a los científicos en el desarrollo de nuevas terapias para combatir COVID-19, dicen los investigadores.
Los hallazgos se publicaron el 26 de octubre en la revista Cell.
Researchers at Yale University and the Broad Institute of MIT and Harvard screened hundreds of millions of cells exposed to the COVID-19 and MERS viruses and identified genes that both enable the viruses to replicate in cells and those that may prevent it.
-
Tuesday 27 Oct 2020
Cough.. the eternal problem!
These guidelines incorporate the recent advances in chronic cough pathophysiology, diagnosis and treatment. The concept of cough hypersensitivity has allowed an umbrella term that explains the exquisite sensitivity of patients to external stimuli such a cold air, perfumes, smoke and bleach. Thus, ad...
-
Tuesday 27 Oct 2020
Εξαιρετική ενημέρωση από την ΕΠΕ!!!
-
Tuesday 27 Oct 2020
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.
Inhaled liposomal ciprofloxacin (ARD-3150) resulted in significant improvements in respiratory symptoms during the on-treatment periods which were lost during off-treatment periods. These results supports the concept that reducing bacterial load can improve respiratory symptoms in patients with bronchiectasis.
It is not known if inhaled antibiotics improve respiratory symptoms in patients with bronchiectasis. In the recent phase-3 ORBIT trials, 48 weeks' treatment with ARD-3150 (inhaled liposomal ciprofloxacin) did not significantly improve symptoms using the prespecified method of analysis comparing base...
-
Tuesday 27 Oct 2020
Epidemic forecasting has a dubious track-record, and its failures became more prominent with COVID-19. Poor data input, wrong modeling assumptions, high sensitivity of estimates, lack of incorporation of epidemiological features, poor past evidence on effects of available interventions, lack of transparency, errors, lack of determinacy, consideration of only one or a few dimensions of the problem at hand, lack of expertise in crucial disciplines, groupthink and bandwagon effects, and selective reporting are some of the causes of these failure
Epidemic forecasting has a dubious track-record, and its failures became more prominent with COVID-19. Poor data input, wrong modeling assumptions, hi…
-
Tuesday 27 Oct 2020
Does chemotherapy reactivate SARS-CoV-2 in cancer patients recovered from prior COVID-19 infection?
Recovered COVID-19 cancer patients remain negative in the short-term for SARS-CoV-2 after delivery of chemotherapy. The knowledge/experience gained from this study may aid guidelines on delivering chemotherapy to cancer patients recovered from COVID-19 infection during this pandemic as well as to address potential “second waves” in the future.
Cancer patients are particularly vulnerable to coronavirus disease 2019 (COVID-19) [1–3]. These individuals are not only more susceptible to this infection, but also more frequently develop severe pneumonia during the disease course [1–3]. One factor associated with an increasing risk for develo...
-
Tuesday 27 Oct 2020
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid.
Therapeutic drug monitoring (TDM) for isoniazid using saliva samples will not be an equivalent alternative to traditional TDM, as already shown for moxifloxacin and amikacin, but it can be useful in home screening of rifampicin drug exposure in patients with TB, as has been established for linezolid and levofloxacin.
The persisting worldwide burden of tuberculosis (TB) is worrisome. In 2018, an estimated 10 million individuals developed TB and 1.45 million infected individuals died [1]. The increase in drug resistance is an important point of concern. Resistance can be acquired by inappropriate drug manageme...
-
Tuesday 27 Oct 2020
Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients.
Elevated D-dimers (>2590 ng·mL−1) and absence of anticoagulant therapy predict PE in hospitalised COVID-19 patients with clinical signs of severity. These data strengthen the evidence base in favour of systematic anticoagulation, and suggest wider use of D-dimer guided CTPA to screen for PE in acutely ill hospitalised patients with COVID-19.
Background Coronavirus disease 2019 (COVID-19) may predispose to venous thromboembolism. We determined factors independently associated with computed tomography pulmonary angiography (CTPA)-confirmed pulmonary embolism (PE) in hospitalised severe COVID-19 patients. Methods Among all (n=349) patients...
-
Tuesday 27 Oct 2020
Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis
High levels of active neutrophil elastase are associated to low microbiome diversity and specifically to P. aeruginosa infection.
Introduction Neutrophilic inflammation is a major driver of bronchiectasis pathophysiology, and neutrophil elastase activity is the most promising biomarker evaluated in sputum to date. How active neutrophil elastase correlates with the lung microbiome in bronchiectasis is still unexplored. We aimed...
-
Tuesday 27 Oct 2020
Can UV Light Kill the New Coronavirus?
UVC light can effectively kill SARS-CoV-2 or other coronaviruses in liquids, on surfaces, or in the air. Due to the fact that it presents less of a health hazard, far-UVC may be a good option for disinfection.
The type of UV light that’s most effective at killing germs, like the new coronavirus, is UVC light, especially far-UVC light, which is emitted at a specific wavelength and is less harmful to humans.
-
Tuesday 27 Oct 2020
COVID-19-Induced Anosmia and Ageusia Are Associated with Younger Age and Lower Blood Eosinophil Counts.
COVID-19 patients with anosmia and ageusia are more likely to have systemic, respiratory, and gastrointestinal symptoms. Anosmia and ageusia were more common among younger patients and those with lower blood eosinophil counts. Ageusia was less commonly reported among men, and time to taste recovery was earlier among both men and Latinos.
Background: Anosmia and ageusia are symptoms commonly associated with COVID-19, but the relationship with disease severity and recovery are unclear. In this stu
-
Monday 26 Oct 2020
In COPD, pharmacotherapy ameliorates rate of lung function decline. The relative benefit observed is within the range of those reported for health status and exacerbations in the same studies. Guidelines should be adjusted according to these findings.
In COPD, pharmacotherapy ameliorates rate of lung function decline. The relative benefit observed is within the range of those reported for health status and exacerbations in the same studies. Guidelines should be adjusted according to these findings.
